PT2506840T - Utilizações de inibidores de fatores induzíveis de hipoxia - Google Patents

Utilizações de inibidores de fatores induzíveis de hipoxia

Info

Publication number
PT2506840T
PT2506840T PT108348830T PT10834883T PT2506840T PT 2506840 T PT2506840 T PT 2506840T PT 108348830 T PT108348830 T PT 108348830T PT 10834883 T PT10834883 T PT 10834883T PT 2506840 T PT2506840 T PT 2506840T
Authority
PT
Portugal
Prior art keywords
hypoxia
inducible factor
factor inhibitors
inhibitors
inducible
Prior art date
Application number
PT108348830T
Other languages
English (en)
Original Assignee
Oncoc4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoc4 Inc filed Critical Oncoc4 Inc
Publication of PT2506840T publication Critical patent/PT2506840T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT108348830T 2009-12-04 2010-06-25 Utilizações de inibidores de fatores induzíveis de hipoxia PT2506840T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26685609P 2009-12-04 2009-12-04

Publications (1)

Publication Number Publication Date
PT2506840T true PT2506840T (pt) 2021-04-27

Family

ID=44115219

Family Applications (1)

Application Number Title Priority Date Filing Date
PT108348830T PT2506840T (pt) 2009-12-04 2010-06-25 Utilizações de inibidores de fatores induzíveis de hipoxia

Country Status (14)

Country Link
US (7) US9427413B2 (pt)
EP (2) EP3892264A3 (pt)
CN (2) CN102791260A (pt)
CA (1) CA2782527C (pt)
CY (1) CY1125365T1 (pt)
DK (1) DK2506840T3 (pt)
ES (1) ES2864743T3 (pt)
HR (1) HRP20210537T1 (pt)
HU (1) HUE053793T2 (pt)
LT (1) LT2506840T (pt)
PL (1) PL2506840T3 (pt)
PT (1) PT2506840T (pt)
SI (1) SI2506840T1 (pt)
WO (1) WO2011068563A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011068563A1 (en) 2009-12-04 2011-06-09 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors
CN103007293B (zh) * 2012-12-30 2014-04-02 中国人民解放军第三军医大学第一附属医院 具有靶向性的多肽-基因复合物及其制备方法和应用
WO2017031341A1 (en) * 2015-08-19 2017-02-23 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease
WO2017083403A1 (en) 2015-11-10 2017-05-18 Children's Research Institute, Children's National Medical Center Echinomycin formulation, method of making and method of use thereof
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
EP3612187B1 (en) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018213751A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
MX2019014806A (es) 2017-06-26 2020-02-10 Lunella Biotech Inc Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas.
CN110669871A (zh) * 2019-10-17 2020-01-10 河北森朗生物科技有限公司 一种慢病毒转导滴度的测定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643871A (en) 1993-11-23 1997-07-01 Bristol-Meyers Squibb Company Antitumor antibiotics
US6416956B1 (en) * 1999-08-13 2002-07-09 George Washington University Transcription factor, BP1
WO2002034291A2 (en) 2000-10-26 2002-05-02 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
AU2004251890B2 (en) * 2003-06-25 2010-09-23 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
CN1233844C (zh) * 2003-09-05 2005-12-28 上海第二医科大学附属瑞金医院 HIF－1α在治疗白血病药物的筛选中的应用
AU2005280112B2 (en) * 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
JP5011277B2 (ja) * 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
WO2007130037A1 (en) * 2006-05-02 2007-11-15 Emory University Hif-1 inhibitors and methods of use thereof
ES2556677T3 (es) 2006-08-02 2016-01-19 Sunesis Pharmaceuticals, Inc. Utilización combinada de ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico y citarabina (Ara-C) para el tratamiento de la leucemia
WO2008128169A1 (en) * 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
WO2009049258A1 (en) * 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
WO2011068563A1 (en) 2009-12-04 2011-06-09 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors

Also Published As

Publication number Publication date
US20120264697A1 (en) 2012-10-18
HUE053793T2 (hu) 2021-07-28
DK2506840T3 (da) 2021-04-12
US9623070B2 (en) 2017-04-18
EP2506840A4 (en) 2013-07-03
CA2782527A1 (en) 2011-06-09
ES2864743T3 (es) 2021-10-14
EP2506840B1 (en) 2021-01-06
LT2506840T (lt) 2021-06-25
EP2506840A1 (en) 2012-10-10
US20190255140A1 (en) 2019-08-22
US9877998B2 (en) 2018-01-30
CN109224064A (zh) 2019-01-18
US20210161991A1 (en) 2021-06-03
PL2506840T3 (pl) 2021-10-11
US20170035832A1 (en) 2017-02-09
CN102791260A (zh) 2012-11-21
US20180177841A1 (en) 2018-06-28
HRP20210537T1 (hr) 2021-05-14
CA2782527C (en) 2019-09-17
SI2506840T1 (sl) 2021-08-31
US9427413B2 (en) 2016-08-30
US20200147167A1 (en) 2020-05-14
CY1125365T1 (el) 2024-02-16
EP3892264A2 (en) 2021-10-13
WO2011068563A1 (en) 2011-06-09
US20170239315A1 (en) 2017-08-24
EP3892264A3 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
EP2424873A4 (en) NEW GALACTOSID INHIBITORS OF GALECTINES
HK1165425A1 (zh) 作為 抑制劑的 -環烷基氨基喹諾酮
GB201701948D0 (en) Releasable corrosion inhibitors
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
LT2506840T (lt) Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
ZA201206456B (en) Uses of dgati inhibitors
HK1171624A1 (en) Inhibitors of cognitive decline
HK1167323A1 (en) Inhibitors of cognitive decline
HK1215187A1 (zh) 炎症性疾病的抑制劑
EP2413941A4 (en) INHIBITORS OF THE RENIN
GB0901898D0 (en) Dual calpain-ros inhibitors
EP2496230A4 (en) INHIBITORS OF IRE-1 ALPHA
EP2488032A4 (en) PROSTAGLAND INTRANSPORTERMER AND ITS USE
EP2467385A4 (en) INHIBITORS OF REINE
IL217756A0 (en) Inhibitors of jnk
PL2411376T3 (pl) Inhibitory nf-kb
EP2346829A4 (en) INHIBITORS OF STAT3
GB0901900D0 (en) Dual calpain-ros inhibitors
GB0908609D0 (en) New use of isoQC inhibitors
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
GB0903651D0 (en) Inhibitors of glyoxalase
GB0915927D0 (en) Novel inhibitors
GB0902661D0 (en) Inhibitors
GB0903650D0 (en) Glyoalase inhibitors